Mineralys Therapeutics financials
$24.48−4.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$170.6M | -$192.4M | -$84.7M |
| Net income | -$154.7M | -$177.8M | -$71.9M |
| Net margin | — | — | — |
| Diluted EPS | $-2.29 | $-3.66 | $-1.99 |
| EBITDA | -$170.5M | -$192.4M | -$84.7M |
| Operating cash flow | -$142.4M | -$166.3M | -$81.2M |
| Free cash flow | -$142.4M | -$166.4M | -$81.2M |
| Diluted shares | 67.7M | 48.5M | 36.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $172.9M | $114.1M | $49.3M |
| Short-term investments | $483.7M | $84.1M | $187.3M |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $661.8M | $205.9M | $251.6M |
| Total liabilities | $15.1M | $14.6M | $10.5M |
| Shareholders' equity | $646.7M | $191.3M | $241.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology